৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Quantity:
Products
Payment
Delivery
Indications
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of use:
Not studied in patients with history of pancreatitis.
Not indicated for type 1 diabetes mellitus.
Pharmacology
Tirzepatide is a dual GIP receptor and GLP-1 receptor agonist.
Modified peptide (39 amino acids) with fatty diacid moiety for albumin binding → prolonged half-life.
Enhances first- and second-phase insulin secretion, reduces glucagon levels in a glucose-dependent manner.
Dosage & Administration
Route: Subcutaneous injection.
Starting dose: 2.5 mg once weekly (initiation only, not for glycemic control).
After 4 weeks: increase to 5 mg once weekly.
Further increases: in 2.5 mg increments every ≥4 weeks, up to max 15 mg once weekly.
Missed dose: administer within 4 days; if >4 days, skip and resume regular schedule.
Weekly administration day can be changed if ≥3 days between doses.
Injection sites: abdomen, thigh, upper arm (rotate sites).
Do not mix with insulin; if used together, inject separately in same region but not adjacent.
Do not freeze; protect pre-filled syringes from light; inspect visually before use.
Interactions
Reduce dose of insulin or secretagogues (e.g., sulfonylureas) to lower hypoglycemia risk.
Delays gastric emptying → may affect absorption of oral drugs (e.g., warfarin).
Oral contraceptives: advise switching to non-oral or add barrier method for 4 weeks after initiation and after each dose escalation.
Non-oral contraceptives not affected.
Contraindications
Hypersensitivity to tirzepatide or components.
Personal/family history of medullary thyroid carcinoma (MTC).
Patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).
Side Effects
Common: nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain.
Pregnancy & Lactation
Risks associated with poorly controlled diabetes in pregnancy.
Use only if benefits outweigh risks.
Excreted in milk (animal data); breastfeeding risks cannot be excluded.
Precautions & Warnings
Counsel patients on risk of MTC; monitor for thyroid tumor symptoms.
Monitor for pancreatitis; discontinue if suspected.
Hypoglycemia risk when combined with insulin or secretagogues.
Monitor renal function, especially with severe GI adverse reactions.
Monitor progression of diabetic retinopathy.
If gallstones suspected, perform diagnostic studies.
Hypersensitivity reactions: discontinue immediately.
Use in Special Populations
Not established in children <18 years.
Overdose Effects
Supportive treatment based on symptoms.
Observation may be required; half-life ~5 days.


Tirzepatide is an injectable medication used for type 2 diabetes management and, in many cases, weight management. It works as a dual agonist of GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, helping regulate blood sugar and appetite.
Tirzepatide helps lower blood glucose levels, improve insulin sensitivity, reduce appetite, and support significant weight loss. It may also reduce cardiovascular risk factors in patients with type 2 diabetes.





